In this second webinar of a 2-part series, we will focus on the investor perspective on how to spin out a successful biotech company.
In this session, chaired by Neelam Panchal, Senior Commercialisation of Research and Investment Manager at the Cell and Gene Therapy Catapult, a panel of experienced investors will provide expert insights on:
- The investment landscape for cell and gene therapy companies
- Strategies to de-risk and overcome funding challenges at the preclinical stage
- The role of pharma partnerships in providing expertise and co-development opportunities
- How trends in cell and gene therapy company exits are shaping early-stage funding strategies
- How long technology should be incubated in academia before spinning out
Panellists:
- Nilay Thaker, Principal, ARCH Venture Partners
- Michael Kyriakides, Principal, Syncona
- Karolina Zapadka, Senior Investment Manager, Parkwalk Advisors
Who should attend?
We strongly recommend that early-stage biotech founders, academic researchers considering commercialisation, and stakeholders in cell and gene therapy ventures should attend this webinar. Whether you're seeking funding or looking to understand the investor mindset, this session offers actionable insights to refine your strategy and increase your chances of success.